A Reconsideration of the Link between the Energetics of Water and of ATP Hydrolysis Energy in the Power Strokes of Molecular Motors in Protein Structures

Mechanical energy from oxygen metabolism by mammalian tissues has been studied since 1837. The production of heat by mechanical work was studied by Fick in about 1860. Prior to Fick’s work, energetics were revised by Joule’s experiments which founded the First Law of Thermodynamics. Fenn in 1923/24 found that frog muscle contractions generated extra heat proportional to the amount of work done in shortening the muscle. This was fully consistent with the Joule, Helmholtz concept used for the First Law of Thermodynamics. The link between the energetics of water and ATP hydrolysis in molecular motors is recommended for reconsideration

Critical Roles of Two Hydrophobic Residues within Human Glucose Transporter 9 (hSLC2A9) in Substrate Selectivity and Urate Transport

High blood urate levels (hyperuricemia) have been found to be a significant risk factor for cardiovascular diseases and inflammatory arthritis, such as hypertension and gout. Human glucose transporter 9 (hSLC2A9) is an essential protein that mainly regulates urate/hexose homeostasis in human kidney and liver. hSLC2A9 is a high affinity-low capacity hexose transporter and a high capacity urate transporter. Our previous studies identified a single hydrophobic residue in trans-membrane domain 7 of class II glucose transporters as a determinant of fructose transport. A mutation of isoleucine 335 to valine (I355V) in hSLC2A9 can reduce fructose transport while not affecting glucose fluxes. This current study demonstrates that the I335V mutant transports urate similarly to the wild type hSLC2A9; however, Ile-335 is necessary for urate/fructose trans-acceleration exchange to occur. Furthermore, Trp-110 is a critical site for urate transport. Two structural models of the class II glucose transporters, hSLC2A9 and hSLC2A5, based on the crystal structure of hSLC2A1 (GLUT1), reveal that Ile-335 (or the homologous Ile-296 in hSLC2A5) is a key component for protein conformational changes when the protein translocates substrates. The hSLC2A9 model also predicted that Trp-110 is a crucial site that could directly interact with urate during transport. Together, these studies confirm that hSLC2A9 transports both urate and fructose, but it interacts with them in different ways. Therefore, this study advances our understanding of how hSLC2A9 mediates urate and fructose transport, providing further information for developing pharmacological agents to treat hyperuricemia and related diseases, such as gout, hypertension, and diabetes

A qualitative study of health care professionals' views and experiences of paediatric advance care planning

Background Good end-of-life care planning is vital to ensure optimal care is provided for patients and their families. Two key factors are open and honest advance care planning conversations between the patient (where possible), family, and health care professionals, focusing on exploring what their future wishes are; and the development of an advance care plan document. However, in paediatric and neonatal settings, there has been little research to demonstrate how advance care planning conversations take place. This study explored health care professionals’ views and experiences of paediatric advance care planning in hospitals, community settings and hospices. MethodsA qualitative methodology was employed using purposive sampling of health care professionals involved in the end-of-life care for children aged 0–18 years known to the hospital palliative care team, and had died at least three months before, but less than 18 months prior to the study. Ethics committee approval was obtained for the study. Located in the North of England, the study involved three hospitals, a children’s hospice, and community services. Data were collected using semi-structured, digitally recorded, telephone interviews. All interviews were transcribed verbatim and subjected to thematic analysis. ResultsTwenty-one health care professionals participated, including generalist paediatric staff as well as specialist palliative care staff.Two themes were generated from the study: The timing of planning conversations, including waiting for the relationship with the family to form; the introduction of parallel planning; avoiding a crisis situation. Secondly, supporting effective conversations around advance care planning, including where to have the conversation; introducing the conversation; and how to approach the topic encompassing the value of advance care planning and documentation for families. Conclusion The timing of when to start the advance care planning conversations remains an issue for health care professionals. The value of doing it in stages and considering the environment where the conversations are held was noted. Timely planning was seen as vital to avoid difficult conversations at a crisis point and for co-ordination of care. Good advance care planning is to provide the best person-centred care for the child and experience for the family

Blended foods for tube-fed children: a safe and realistic option? A rapid review of the evidence

With the growing number of children and young people with complex care needs or life-limiting conditions, alternative routes for nutrition have been established (such as gastrostomy feeding). The conditions of children and young people who require such feeding are diverse but could relate to problems with swallowing (dysphagia), digestive disorders or neurological/muscular disorders. However, the use of a blended diet as an alternative to prescribed formula feeds for children fed via a gastrostomy is a contentious issue for clinicians and researchers. From a rapid review of the literature, we identify that current evidence falls into three categories: (1) those who feel that the use of a blended diet is unsafe and substandard; (2) those who see benefits of such a diet as an alternative in particular circumstances (eg, to reduce constipation) and (3) those who see merit in the blended diet but are cautious to proclaim potential benefits due to the lack of clinical research. There may be some benefits to using blended diets, although concerns around safety, nutrition and practical issues remain

Models of lon and substrate cotransport and the effect of the membrane potential

The implications of a carrier model of ion and substrate cotransport are worked out. Each carrier is assumed to have one ion and one substrate binding site. The model includes features that have not been included in previously published models. These features are the effect of the membrane potential and of the assumption that all carrier forms, with or without bound substrate and with or without various bound ions, can cross the membrane. The model is of a two-state (gate-type) carrier with transition rate constants. In one state the carrier interacts with outer bulk phase; in the other state it interacts with the inner bulk phase. Equilibrium in the reactions between ion, substrate, and carrier is assumed at each surface.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34163/1/0000451.pd

Current technical approaches to brain energy metabolism

Neuroscience is a technology‐driven discipline and brain energy metabolism is no exception. Once satisfied with mapping metabolic pathways at organ level, we are now looking to learn what it is exactly that metabolic enzymes and transporters do and when, where do they reside, how are they regulated, and how do they relate to the specific functions of neurons, glial cells, and their subcellular domains and organelles, in different areas of the brain. Moreover, we aim to quantify the fluxes of metabolites within and between cells. Energy metabolism is not just a necessity for proper cell function and viability but plays specific roles in higher brain functions such as memory processing and behavior, whose mechanisms need to be understood at all hierarchical levels, from isolated proteins to whole subjects, in both health and disease. To this aim, the field takes advantage of diverse disciplines including anatomy, histology, physiology, biochemistry, bioenergetics, cellular biology, molecular biology, developmental biology, neurology, and mathematical modeling. This article presents a well‐referenced synopsis of the technical side of brain energy metabolism research. Detail and jargon are avoided whenever possible and emphasis is given to comparative strengths, limitations, and weaknesses, information that is often not available in regular articles.Fondecyt, Grant Number: 1160317; MINECO, Grant Numbers: SAF2016‐78114‐R and RTC‐2015‐3237‐1; CIBERFES, Grant Numer: CB16/10/00282; SP3‐People‐MC‐ITN program, Grant Number: 608381; EU BATCure, Grant Number: 666918; FEDER (European regional development fund); Investissement d'Avenir, Grant Number: ANR‐11‐INBS‐0011; French State in the context of the “Investments for the future” Program IdEx and the LabEx TRAIL, Grant Numbers: ANR‐10‐IDEX and ANR‐10‐LABX‐57; French–Swiss ANR‐FNS, Grant Numer: ANR‐15‐ CE37‐0012. University of Nottingham; BBSRC, Grant Numers: BB/L019396/1 and BB/K009192/1; MRC, Grant Number: MR/L020661/1; Deutsche Forschungsgemeinschaft, Grant Numers: DFG SPP 1757, SFB 894, and FOR 2289; European Commission, Grant Number: H2020‐FETPROACT 732344; Neurofibres, Grant Number: H2020‐MSCA‐ITN‐722053 EU‐GliaPhD; US National Institutes of Health, Grant Number: R01NS087611; Teva Pharmaceuticals; Agilent Technologies. IdEx, Grant Number: ANR‐10‐IDEX‐03‐02; French–Swiss ANR‐FNS, Grant number: 310030E‐164271; National Institutes of Neurologic Disease and Stroke at the National Institutes of Health, Grant Numer: R01 NS077773; University of Zurich and the Swiss National Science Foundation; Comisión Nacional de Investigación Científica y Tecnológica, Grant Numer: PB 01; Fondo Nacional de Desarrollo Científico y Tecnológico, Grant Numer: 1160317; Ministerio de Economía y Competitividad, Grant Numer: RTC‐2015‐3237‐1,SAF2016‐78114‐R; Agence Nationale de la Recherche, Grant Numers: ANR‐10‐IDEX, ANR‐10‐IDEX‐03‐02, ANR‐10‐LABX‐57, ANR‐11‐INBS‐0011, and ANR‐15‐ CE37‐0012; Biotechnology and Biological Sciences Research Council, Grant Numers: BB/L019396/1 and BB/K009192/1; Medical Research Council, Grant Numer: MR/L020661/1.Peer reviewe